Showing results (301-310 of 699) with videos related to
Sort By:
Pageof 70
The New England Journal of Medicine|February 22, 2002
A long-term study of prognosis in monoclonal gammopathy of undetermined significanceRobert A Kyle, Terry M Therneau, S Vincent Rajkumar, et al.Oncotarget|October 24, 2018
Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myelomaUtkarsh Painuly, Vijay Ramakrishnan, Teresa Kimlinger, et al.British Journal of Haematology|June 8, 2017
Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myelomaShaji K Kumar, Jacob P Laubach, Thomas J Giove, et al.Blood Cancer Journal|May 19, 2019
Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathiesShaji Kumar, Dirk R Larson, Angela Dispenzieri, et al.Clinical Chemistry|June 13, 2009
Screening panels for detection of monoclonal gammopathiesJerry A Katzmann, Robert A Kyle, Joanne Benson, et al.Clinical Lymphoma, Myeloma & Leukemia|March 16, 2013
Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemiaRobert A Kyle, Terry M Therneau, Angela Dispenzieri, et al.Cancer|October 10, 2013
Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategiesBrian L Burnette, Angela Dispenzieri, Shaji Kumar, et al.Blood|July 31, 2009
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myelomaCheng E Chee, Shaji Kumar, Dirk R Larson, et al.Clinical Chemistry|April 28, 2007
Comparison of bromcresol green and agarose protein electrophoresis for quantitation of serum albumin in multiple myelomaChristine L H Snozek, Amy K Saenger, Philip R Greipp, et al.Cancer|November 20, 2009
Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myelomaEric W Schaefer, Shaji Kumar, Angela Dispenzieri, et al.Pageof 70